Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Zappasodi

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Biorxiv : the Preprint Server for Biology|May 13, 2026
A tumor metabolism-angiogenesis-immune axis governs immunotherapy responsesInna Serganova, Giorgia Colombo, Francesco Ballesio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Nature Communications|August 13, 2020
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-KynurenineLuis Felipe Campesato, Sadna Budhu, Jeremy Tchaicha, et al.
Nature Immunology|February 19, 2020
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumorsHaiping Wang, Fabien Franco, Yao-Chen Tsui, et al.
The Journal of Clinical Investigation|July 23, 2019
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumorsDanny N Khalil, Nathan Suek, Luis Felipe Campesato, et al.
Nature Immunology|November 17, 2025
Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancerChien-Huan Weng, Anais Assouvie, Lauren Dong, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.
Nature Communications|April 3, 2024
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironmentJie Li, Christopher R Chin, Hsia-Yuan Ying, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Biorxiv : the Preprint Server for Biology|May 13, 2026
A tumor metabolism-angiogenesis-immune axis governs immunotherapy responsesInna Serganova, Giorgia Colombo, Francesco Ballesio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Nature Communications|August 13, 2020
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-KynurenineLuis Felipe Campesato, Sadna Budhu, Jeremy Tchaicha, et al.
Nature Immunology|February 19, 2020
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumorsHaiping Wang, Fabien Franco, Yao-Chen Tsui, et al.
The Journal of Clinical Investigation|July 23, 2019
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumorsDanny N Khalil, Nathan Suek, Luis Felipe Campesato, et al.
Nature Immunology|November 17, 2025
Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancerChien-Huan Weng, Anais Assouvie, Lauren Dong, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.
Nature Communications|April 3, 2024
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironmentJie Li, Christopher R Chin, Hsia-Yuan Ying, et al.
Pageof 7